Felicity Thomas is the former Associate Editorial Director of Pharmaceutical Technology, Pharmaceutical Technology Europe, BioPharm International.

Articles

The power of collaboration is a critically important for the bio/pharma industry.

A New “Voyage”

Wider life sciences industries in the UK and Europe are receiving favourable financial support from governing bodies.  

Budget Benefit

Mike Hennessy Jr. is the Chairman and CEO of 

While Catalent’s acquisition is definitely about making drugs, it’s also very much about making money.

First in Line on Catalent’s Line

The partnership will allow for both companies to provide end-to-end biopharmaceutical manufacturing solutions.

BioCina and NovaCina to Partner on Drug Substance and Product Solutions for Biologics

Feliza Mirasol is the science editor for 

CordenPharma’s new starter kits are designed to enable effective formulation in the development of mRNA-based therapeutics.

CordenPharma Launches New LNP Starter Kits for mRNA Formulation

The company is investing more than $250 million into its Bloomington, Ind. Manufacturing site.

Simtra BioPharma Solutions Expands Sterile Fill/Finish Manufacturing Site

Nona Biosciences and Boostimmune will collaborate to develop ADCs against novel targets using Nona’s proprietary platform technology.

Nona Biosciences Partners with Boostimmune on ADC Development

Chris Spivey is director of Industry Relations and Strategic Partnership, MJH Life Sciences.

Steffen Thirstrup, chief medical officer, EMA, emphasizes the importance of transparency in investigating potential safety issues of CAR-T therapies, while highlighting the need to balance regulatory diligence with maintaining trust within the community and among stakeholders.

Europa Perspectives: EMA Transparency in Investigating CAR-T Secondary Cancers

CSL will share access to Cytegrity, its proprietary stable production system for lentiviral vector production, with Genezen. 

CSL Licenses Cytegrity Lentiviral Vector Production System to Genezen

The agency has recommended granting marketing authorization to ALS treatment, Qalsody (tofersen), for adults who have a mutation in the superoxide dismutase 1 (SOD1) gene.

News